Cargando…

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD

BACKGROUND: For treatment of neovascular age-related macular degeneration (nAMD), multiple intravitreal injections of drugs targeting vascular endothelial growth factors (VEGF) result in a high burden for patients and healthcare systems. Low-energy stereotactic radiotherapy (SRT) might reduce the an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatz, Katja, Zimmermann, Frank, Lazaridis, Emmanouil, Kardamakis, Dimitrios, Guichard, Magdalena, Türksever, Cengiz, Pruente, Christian, Schmidt-Erfurth, Ursula Margarethe, Gerendas, Bianca S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867264/ https://www.ncbi.nlm.nih.gov/pubmed/33355151 http://dx.doi.org/10.1136/bjophthalmol-2020-317563

Ejemplares similares

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
por: Tuerksever, Cengiz, et al.
Publicado: (2021)

Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls
por: Türksever, Cengiz, et al.
Publicado: (2023)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Ganglion cell layer thickening in well‐controlled patients with type 1 diabetes: an early sign for diabetic retinopathy?
por: Gerendas, Bianca S., et al.
Publicado: (2019)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
por: Lüke, Jan Niklas, et al.
Publicado: (2022)

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
por: Ebneter, Andreas, et al.
Publicado: (2020)

The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3
por: Haj Najeeb, Bilal, et al.
Publicado: (2021)

Polarisation-sensitive OCT is useful for evaluating retinal pigment epithelial lesions in patients with neovascular AMD
por: Schütze, Christopher, et al.
Publicado: (2016)

Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning
por: Holomcik, David, et al.
Publicado: (2022)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
por: Clearkin, Louis, et al.
Publicado: (2019)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3
por: Haj Najeeb, Bilal, et al.
Publicado: (2021)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
por: Bulirsch, Louisa Maria, et al.
Publicado: (2022)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Association of microvascular biomarkers in fluorescein angiography with macrovascular-related mortality in clinical routine data
por: Goldbach, Felix, et al.
Publicado: (2022)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
por: Hoffmann, Laura, et al.
Publicado: (2021)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months
por: Haj Najeeb, Bilal, et al.
Publicado: (2022)

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
por: Heier, Jeffrey S., et al.
Publicado: (2022)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
por: Lynch, Stephanie K., et al.
Publicado: (2019)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis
por: Roberts, Philipp Ken, et al.
Publicado: (2021)

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
por: Barth, T., et al.
Publicado: (2019)

Contrast sensitivity and binocular reading speed best correlating with near distance vision‐related quality of life in bilateral nAMD
por: Rossouw, Petra, et al.
Publicado: (2020)

Evaluating the impact of vitreomacular adhesion on anti-VEGF therapy for retinal vein occlusion using machine learning
por: Waldstein, Sebastian M., et al.
Publicado: (2017)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dn8r1mipbuf773e3n8fl1v39eb